The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chatenoud, L.
Right arrow Articles by Bach, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chatenoud, L.
Right arrow Articles by Bach, J. F.

The Journal of Immunology, Vol 158, Issue 6 2947-2954, Copyright © 1997 by American Association of Immunologists

ARTICLES

CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice

L Chatenoud, J Primo and JF Bach
INSERM Unit 25, The Necker Hospital, Paris, France.

Low doses of the CD3 mAb 145 2C11 restored self tolerance to beta cell Ags in adult overtly diabetic NOD mice. Within 2 to 4 wk after treatment, complete and permanent remission of diabetes was observed. Autoreactive T cells were not deleted in CD3 Ab-protected animals as evidenced first, by the persistence of peripheral insulitis and, second, by the capacity of spleen cells from CD3 Ab-treated mice to transfer diabetes to adult irradiated syngeneic recipients. Moreover, the conferred tolerance was reproducibly reversed by a single injection of cyclophosphamide. For 5 to 7 wk after treatment, IFN-gamma production by stimulated spleen cells was significantly decreased in treated animals. One unique feature was that the CD3 Ab-induced tolerance ensued only from treatment of overtly diabetic NOD mice. Durable protection was exclusively observed when treating mice with recent onset disease (14-20 wk old). At variance with this finding, treatment of 4- and 8-wk-old mice was without effect, and complete but transient protection followed the treatment of 12-wk-old NOD mice. The tolerogenic properties of 145 2C11 did not depend on its mitogenic capacity, since nonmitogenic F(ab')2 fragments also appeared potent at inducing durable remission in overtly diabetic NOD, although nonmitogenic CD3 F(ab')2 fragments could mediate T cell signaling, as evidenced by cytokine gene transcription (IL-2, IFN-gamma, IL-4, and IL- 10) assessed by PCR on splenocytes from treated mice. A concomitant cyclosporine treatment abrogated the CD3 mAb-induced protection, further pointing to the crucial role of T cell signaling in the effect observed.


This article has been cited by other articles:


Home page
 BloodHome page
B. Peng, P. Ye, D. J. Rawlings, H. D. Ochs, and C. H. Miao
Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy
Blood, November 12, 2009; 114(20): 4373 - 4382.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Y. Zouggari, H. Ait-Oufella, L. Waeckel, J. Vilar, C. Loinard, C. Cochain, A. Recalde, M. Duriez, B. I. Levy, E. Lutgens, et al.
Regulatory T Cells Modulate Postischemic Neovascularization
Circulation, October 6, 2009; 120(14): 1415 - 1425.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. D. Norquay, K. E. D'Aquino, L. M. Opare-Addo, A. Kuznetsova, M. Haas, J. A. Bluestone, and M. F. White
Insulin Receptor Substrate-2 in {beta}-Cells Decreases Diabetes in Nonobese Diabetic Mice
Endocrinology, October 1, 2009; 150(10): 4531 - 4540.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Begum, W. Chen, K. C. Herold, and V. E. Papaioannou
Remission of Type 1 Diabetes after Anti-CD3 Antibody Treatment and Transplantation of Embryonic Pancreatic Precursors
Endocrinology, October 1, 2009; 150(10): 4512 - 4520.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. J. Parker, S. Xue, J. J. Alexander, C. H. Wasserfall, M. L. Campbell-Thompson, M. Battaglia, S. Gregori, C. E. Mathews, S. Song, M. Troutt, et al.
Immune Depletion With Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice
Diabetes, October 1, 2009; 58(10): 2277 - 2284.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. Chen, G. Han, J. Wang, R. Wang, R. Xu, B. Shen, J. Qian, and Y. Li
Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab')2 Antibody Treatment through Secreting Transforming Growth Factor-{beta}
Am. J. Pathol., September 1, 2009; 175(3): 1086 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
H. Wu, E. Center, G. Tsokos, and H. Weiner
Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells
Lupus, June 1, 2009; 18(7): 586 - 596.
[Abstract] [PDF]

Home page
 DiabetesHome page
A. Valle, T. Jofra, A. Stabilini, M. Atkinson, M.-G. Roncarolo, and M. Battaglia
Rapamycin Prevents and Breaks the Anti-CD3-Induced Tolerance in NOD Mice
Diabetes, April 1, 2009; 58(4): 875 - 881.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Waters, M. Qadura, E. Burnett, R. Chegeni, A. Labelle, P. Thompson, C. Hough, and D. Lillicrap
Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response
Blood, January 1, 2009; 113(1): 193 - 203.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. McGargill, C. Choy, B. G. Wen, and S. M. Hedrick
Drak2 Regulates the Survival of Activated T Cells and Is Required for Organ-Specific Autoimmune Disease
J. Immunol., December 1, 2008; 181(11): 7593 - 7605.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Y. Wu, F. J. Quintana, and H. L. Weiner
Nasal Anti-CD3 Antibody Ameliorates Lupus by Inducing an IL-10-Secreting CD4+CD25-LAP+ Regulatory T Cell and Is Associated with Down-Regulation of IL-17+CD4+ICOS+CXCR5+ Follicular Helper T Cells
J. Immunol., November 1, 2008; 181(9): 6038 - 6050.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J. G Mabley, P. Pacher, K. G K Murthy, W. Williams, G. J Southan, A. L Salzman, and C. Szabo
The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes
J. Endocrinol., September 1, 2008; 198(3): 581 - 589.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. A. Sherry, W. Chen, J. A. Kushner, M. Glandt, Q. Tang, S. Tsai, P. Santamaria, J. A. Bluestone, A.-M. B. Brillantes, and K. C. Herold
Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of {beta}-Cells
Endocrinology, November 1, 2007; 148(11): 5136 - 5144.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Ishikawa, H. Ochi, M.-L. Chen, D. Frenkel, R. Maron, and H. L. Weiner
Inhibition of Autoimmune Diabetes by Oral Administration of Anti-CD3 Monoclonal Antibody
Diabetes, August 1, 2007; 56(8): 2103 - 2109.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. You, B. Leforban, C. Garcia, J.-F. Bach, J. A. Bluestone, and L. Chatenoud
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment
PNAS, April 10, 2007; 104(15): 6335 - 6340.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. M. Phillips, L. O'Reilly, C. Bland, A. K. Foulis, and A. Cooke
Patients With Chronic Pancreatitis Have Islet Progenitor Cells in Their Ducts, but Reversal of Overt Diabetes in NOD Mice by Anti-CD3 Shows No Evidence for Islet Regeneration
Diabetes, March 1, 2007; 56(3): 634 - 640.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
X. Luo, K. V. Tarbell, H. Yang, K. Pothoven, S. L. Bailey, R. Ding, R. M. Steinman, and M. Suthanthiran
Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells
PNAS, February 20, 2007; 104(8): 2821 - 2826.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Zhang, I. Todorov, C.-L. Lin, M. Atkinson, F. Kandeel, S. Forman, and D. Zeng
Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice
PNAS, February 13, 2007; 104(7): 2337 - 2342.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
B. T. Fife, I. Guleria, M. Gubbels Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, and J. A. Bluestone
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
J. Exp. Med., November 27, 2006; 203(12): 2737 - 2747.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Steffens, F. Burger, G. Pelli, Y. Dean, G. Elson, M. Kosco-Vilbois, L. Chatenoud, and F. Mach
Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in Mice
Circulation, October 31, 2006; 114(18): 1977 - 1984.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
A. Tedgui and Z. Mallat
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Physiol Rev, April 1, 2006; 86(2): 515 - 581.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
P. Narendran, E. Estella, and S. Fourlanos
Immunology of type 1 diabetes
QJM, August 1, 2005; 98(8): 547 - 556.
[Full Text] [PDF]

Home page
 NEJMHome page
B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, et al.
Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes
N. Engl. J. Med., June 23, 2005; 352(25): 2598 - 2608.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. C. Herold, S. E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan, and J. A. Bluestone
A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes
Diabetes, June 1, 2005; 54(6): 1763 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. P. Kohm, J. S. Williams, A. L. Bickford, J. S. McMahon, L. Chatenoud, J.-F. Bach, J. A. Bluestone, and S. D. Miller
Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis
J. Immunol., April 15, 2005; 174(8): 4525 - 4534.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Liang, T. Huang, C. Zhang, I. Todorov, M. Atkinson, F. Kandeel, S. Forman, and D. Zeng
Donor CD8+ T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb
Blood, March 1, 2005; 105(5): 2180 - 2188.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. You, G. Slehoffer, S. Barriot, J.-F. Bach, and L. Chatenoud
Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice
PNAS, October 5, 2004; 101(suppl_2): 14580 - 14585.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. A. Bluestone and Q. Tang
Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells
PNAS, October 5, 2004; 101(suppl_2): 14622 - 14626.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Yang, S. Hussain, Q.-S. Mi, P. Santamaria, and T. L. Delovitch
Perturbed Homeostasis of Peripheral T Cells Elicits Decreased Susceptibility to Anti-CD3-Induced Apoptosis in Prediabetic Nonobese Diabetic Mice
J. Immunol., October 1, 2004; 173(7): 4407 - 4416.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Poirot, C. Benoist, and D. Mathis
Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity
PNAS, May 25, 2004; 101(21): 8102 - 8107.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. L. Masteller, M. R. Warner, W. Ferlin, V. Judkowski, D. Wilson, N. Glaichenhaus, and J. A. Bluestone
Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in Autoimmune Diabetes
J. Immunol., November 15, 2003; 171(10): 5587 - 5595.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Q. Tang, J. A. Smith, G. L. Szot, P. Zhou, M.-L. Alegre, K. J. Henriksen, C. B. Thompson, and J. A. Bluestone
CD28/B7 Regulation of Anti-CD3-Mediated Immunosuppression In Vivo
J. Immunol., February 1, 2003; 170(3): 1510 - 1516.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, et al.
Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus
N. Engl. J. Med., May 30, 2002; 346(22): 1692 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Bertry-Coussot, B. Lucas, C. Danel, L. Halbwachs-Mecarelli, J.-F. Bach, L. Chatenoud, and P. Lemarchand
Long-Term Reversal of Established Autoimmunity upon Transient Blockade of the LFA-1/Intercellular Adhesion Molecule-1 Pathway
J. Immunol., April 1, 2002; 168(7): 3641 - 3648.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. G. von Herrath, B. Coon, T. Wolfe, and L. Chatenoud
Nonmitogenic CD3 Antibody Reverses Virally Induced (Rat Insulin Promoter-Lymphocytic Choriomeningitis Virus) Autoimmune Diabetes Without Impeding Viral Clearance
J. Immunol., January 15, 2002; 168(2): 933 - 941.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
A. Quinn, M. Melo, D. Ethell, and Eli. E. Sercarz
Relative resistance to nasally induced tolerance in non-obese diabetic mice but not other I-Ag7-expressing mouse strains
Int. Immunol., October 1, 2001; 13(10): 1321 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
G. T. Tran, N. Carter, X. Y. He, T. S. Spicer, K. M. Plain, M. Nicolls, B. M. Hall, and S. J. Hodgkinson
Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on Th1 cells that is augmented by IL-4
Int. Immunol., September 1, 2001; 13(9): 1109 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
Q. Wu, B. Salomon, M. Chen, Y. Wang, L. M. Hoffman, J. A. Bluestone, and Y.-X. Fu
Reversal of Spontaneous Autoimmune Insulitis in Nonobese Diabetic Mice by Soluble Lymphotoxin Receptor
J. Exp. Med., June 4, 2001; 193(11): 1327 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. A. BLUESTONE, J. B. MATTHEWS, and A. M. KRENSKY
The Immune Tolerance Network: The "Holy Grail" Comes to the Clinic
J. Am. Soc. Nephrol., November 1, 2000; 11(11): 2141 - 2146.
[Full Text]

Home page
 J. Immunol.Home page
J. A. Smith, Q. Tang, and J. A. Bluestone
Partial TCR Signals Delivered by FcR-Nonbinding Anti-CD3 Monoclonal Antibodies Differentially Regulate Individual Th Subsets
J. Immunol., May 15, 1998; 160(10): 4841 - 4849.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. Albert Basson, U. Bommhardt, M. S. Cole, J. Y. Tso, and R. Zamoyska
CD3 Ligation on Immature Thymocytes Generates Antagonist-like Signals Appropriate for CD8 Lineage Commitment, Independently of T Cell Receptor Specificity
J. Exp. Med., April 20, 1998; 187(8): 1249 - 1260.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.